“The FDA’s decision to withdraw Andexxa from the market underscores a critical failure in post-market surveillance and patient safety,” states Greg Vigna, MD, JD, national medical malpractice attorney.
The U.S. Food and Drug Administration announced on December 18, 2025, that Andexxa (coagulation factor Xa recombinant, inactivated-zhzo) will be withdrawn from the U.S. market following alarming safety data showing the drug’s risks outweigh its benefits. AstraZeneca will end all U.S. commercial sales by December 22, 2025.
Andexxa received accelerated FDA approval in 2018 as a reversal agent for patients experiencing life-threatening or uncontrolled bleeding while taking the blood thinners rivaroxaban or apixaban. The drug was designed to quickly reverse the anticoagulant effects of these medications in emergency situations.
Even at initial approval, the FDA required a Boxed Warning for thromboembolic risks—blood clot complications that could lead to stroke, pulmonary embolism, or death.
As a condition of the 2018 accelerated approval, AstraZeneca was required to conduct a randomized controlled trial to verify Andexxa’s clinical benefit. The ANNEXA-I trial compared Andexxa to usual care in patients with intracerebral hemorrhage who were taking rivaroxaban or apixaban.
Dr. Greg Vigna, Board Certified Physical Medicine and Rehabilitation physician and national medical malpractice attorney, states, “The ANNEXA-I trial results presented to the FDA’s advisory committee in November 2024 revealed catastrophic safety signals that should concern every patient who received this medication.”
The trial demonstrated that Andexxa patients faced a doubled risk of serious complications compared to standard care:
Thrombosis rates: Patients receiving Andexxa experienced blood clots at more than double the rate of those receiving usual care (14.6% versus 6.9%).
Earlier onset of clots: Among Andexxa patients who developed thrombotic events, over half (53%) experienced them earlier than patients in the usual care group (only 6.3%).
Fatal thrombotic events: Deaths related to blood clots occurred in 2.5% of Andexxa patients compared to just 0.9% of usual care patients through 30 days—a near tripling of fatal outcomes.
Greg Vigna, MD, JD, says, “Patients who received Andexxa for bleeding emergencies may have been exposed to unnecessary and potentially life-threatening risks. The fact that a safer usual care approach resulted in significantly fewer deaths and complications raises serious questions about informed consent and the decision-making process that led to this drug’s use.”
If you or a loved one received Andexxa treatment, you may want to consider:
Dr. Vigna adds, “This case highlights ongoing concerns with the FDA’s accelerated approval pathway. Andexxa was approved based on surrogate endpoints in healthy volunteers, not actual clinical outcomes in real patients. It took seven years of real-world use before the required confirmatory trial revealed that this drug was causing more harm than good.”
The accelerated approval pathway allows drugs to reach the market based on preliminary evidence, with manufacturers required to conduct post-market studies. However, these confirmatory studies can take years, during which patients may be exposed to products that ultimately prove unsafe or ineffective.
Beyond the ANNEXA-I trial, the FDA noted it has received additional postmarketing safety reports documenting thromboembolic events, including serious and fatal outcomes, in patients treated with Andexxa. This real-world evidence corroborated the controlled trial findings.
“When a drug is withdrawn from the market due to safety concerns of this magnitude, it raises questions about whether patients were adequately warned and whether the benefits truly outweighed the known risks,” states Dr. Vigna.
Patients who experienced complications following Andexxa administration may have grounds for legal action, particularly if they:
The FDA has stated it will continue working with AstraZeneca to keep healthcare providers and the public informed as the company prepares to end sales of Andexxa. Healthcare facilities that currently stock Andexxa will need to identify alternative approaches for managing bleeding in patients taking factor Xa inhibitors.
Greg Vigna, MD, JD, concludes, “The withdrawal of Andexxa should serve as a wake-up call about the need for more rigorous pre-approval testing and faster completion of post-market confirmatory trials. Patients deserve better protection than a system that can take seven years to confirm that an approved drug is causing more deaths than it prevents.”
If you or a loved one experienced complications following Andexxa treatment, Vigna Law Group can help evaluate your case. Our team combines medical expertise with legal advocacy to hold pharmaceutical companies and healthcare providers accountable when patients are harmed.
Dr. Greg Vigna is Board Certified in Physical Medicine and Rehabilitation and a national pharmaceutical liability attorney. He combines his medical training with legal expertise to advocate for patients injured by dangerous drugs and medical devices.
References:
FDA Safety Communication – Update on the Safety of Andexxa (December 18, 2025)
Cellular, Tissue, and Gene Therapies Advisory Committee Meeting (November 21, 2024)
8939 S. Sepulveda Blvd. Suite 102
Los Angeles, CA, 90045
Dr. Greg Vigna, is the principal of Greg Vigna, MD, JD, PLC, a California personal injury law firm, and his law firm has a non-exclusive referral relationship with the attorneys listed within this site. Dr. Vigna, co-counsels with attorneys across the country.